News

You are here

Feb 10, 2015

Roger Prades, Iproteos CSO, is the first author of an article published this January at Angewandte Chemie reporting a novel peptide capable of overcoming the blood-brain barrier. The work has been possible through the collaboration of a team composed by scientists at IRB Barcelona, RCSI, ISD, INA and UB. The BBB-shuttle is a retro-enantio peptide that is protease-resistant, non-toxic and has the ability of transporting cargos of distinct sizes and types across this barrier. It targets the transferrin receptor but it does not compete with transferrin. Therefore, the peptide reported by Dr.

Feb 10, 2015

Ernest Giralt, co-founder of Iproteos, has been awarded with the “Barcelona City” 2014 prize in the category of Experimental Sciences and Technology. The jury has recognized Prof. Giralt for his development of a technology that allows a cytotoxic peptide from the bee poison to target only tumor cells, without affecting the healthy ones, being therefore, a therapeutic approach with application in chemotherapy. The award ceremony has taken place today, 2 days before “Santa Eulàlia day” – Patron Saint of Barcelona.

Feb 10, 2015

The project named “Spark”, which is devoted to the development of a drug (IPR19) for the treatment of the cognitive impairment associated with schizophrenia, has obtained a “RETOS-Colaboración” grant from the Ministry of Economy and Competitiveness of Spain (RTC-2014-1645-1).

Jan 16, 2015

Ernest Giralt, co-founder of Iproteos and SAB chairman, together with Laura Nevola, IRB Barcelona research associate, have just published a review entitled “Modulating protein-protein interactions: the potential of peptides”. The article, released today 16th of January on Chemical Communications, covers the latest progress in the use of peptides as therapeutics. Peptides have not been totally exploited as drugs because of their poor in vivo stability and their inappropriate ADME properties.

Jan 13, 2015

Iproteos will participate on the BIO-Europe Spring 2015. This 9th edition will be held next March from Monday 9th to Wednesday 11th in Paris. Over 2000 delegates, representing more than 1,200 companies took part on the previous BIO-Europe Spring conference, which took place in Turin. BIO-Europe events put together biotechs, pharma companies, finance entities, CRO, CMO and others in order to promote industry growth. In this regard, the partnering meetings are crucial to foster collaborations.

Dec 02, 2014

Iproteos has been selected to present at the 8th edition of the European Venture Summit, next 8-9 Dec in Düsseldorf. The EVS is the leading investment event in Europe for the technological start-ups. In an effort to drive business growth , the meeting puts together innovative ICT, Life Sciences and Cleantech companies with investors and innovation experts. In total, 120 companies, which have been selected through the European Venture Contests, will present in this two-days meeting.